Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2004

View Archived Issues

NO-donating NSAIDs may attenuate neuroinflammation in Alzheimer's disease

New insight into curcumin action against amyloid pathology

Soy derivative phyto SERM relieves menopausal symptoms and improves BMD without side effects

Novel MAO-B inhibitors developed by Roche researchers

Merck KGaA describes new derivatives of the kappa opioid agonist asimadoline

Novel PDE4D inhibitors prepared and tested by Novartis scientists

New benzimidazole-based gastric antisecretory agents claimed by Altana Pharma

Mitsubishi Pharma and Sanofi-Synthelabo present new TPK1 inhibitors

Alcon patent covers new 5-HT2 agonists for glaucoma therapy

Cytovia researchers identify new caspase activators

CV Therapeutics initiates approval-enabling study of Ranexa

Enrollment completed in phase I colorectal cancer study of Cotara

Organon and Meiji Seika sign Japanese agreement for mirtazapine

Meiact AS granules launched in Japan

Remofovir mesylate enters phase II

Research group to study RPI-78M in MS assays

Pfizer to use Nektar PEGylation technology in drug development

Approvable letter for Lumigan-timolol combination

TRX4 evaluated in new phase I study for psoriasis

sNDA submission for Merrem for complicated skin and skin structure infections

VivaGel phase I study moves into third stage of dosing

La Jolla reaches agreement for phase IV Riquent study

Targeting IP-10 for IBD: Protein Design Labs characterizes antibody for clinical development

Novel small molecule immunomodulating agent for eczema/psoriasis therapy

Potent orally active antiinflammatory agent by Bristol-Myers Squibb

First evidence of effective mGlu2 receptor potentiators for schizophrenia therapy by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...